2017
Fragile X targeted pharmacotherapy: lessons learned and future directions
Erickson C, Davenport M, Schaefer T, Wink L, Pedapati E, Sweeney J, Fitzpatrick S, Brown W, Budimirovic D, Hagerman R, Hessl D, Kaufmann W, Berry-Kravis E. Fragile X targeted pharmacotherapy: lessons learned and future directions. Journal Of Neurodevelopmental Disorders 2017, 9: 7. PMID: 28616096, PMCID: PMC5467059, DOI: 10.1186/s11689-017-9186-9.Peer-Reviewed Original ResearchClinical trial rationaleCurrent prescribing practicesDrug targetsAppropriate outcome measuresClinical trial designTreatment development effortsFXS animal modelsNumerous potential drug targetsTrial rationaleGABAergic neurotransmissionPrescribing practicesSyndrome pathophysiologyClinical trialsOutcome measuresTrial designAnimal modelsDrug approachSingle gene disordersPotential drug targetsTreatment developmentPharmacotherapyDrugsPathophysiologyTrial execution
2011
The twin drug approach for novel nicotinic acetylcholine receptor (nAChR) ligands: Synthesis and structure–affinity relationships
Tomassoli I, Eibl C, Wulf M, Papke R, Picciotto M, Gündisch D. The twin drug approach for novel nicotinic acetylcholine receptor (nAChR) ligands: Synthesis and structure–affinity relationships. Biochemical Pharmacology 2011, 82: 1028. DOI: 10.1016/j.bcp.2011.07.016.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply